000283064 001__ 283064
000283064 005__ 20251230103620.0
000283064 0247_ $$2doi$$a10.1002/alz70857_099980
000283064 0247_ $$2pmid$$apmid:41445352
000283064 0247_ $$2pmc$$apmc:PMC12739319
000283064 0247_ $$2ISSN$$a1552-5260
000283064 0247_ $$2ISSN$$a1552-5279
000283064 037__ $$aDZNE-2025-01471
000283064 041__ $$aEnglish
000283064 082__ $$a610
000283064 1001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b0$$eFirst author$$udzne
000283064 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283064 245__ $$aThe Community General Practitioner and General Specialist‐based Cognitive Screening to Identify Early Decline in Seniors in Germany Study (COGSCREEN 2)
000283064 260__ $$c2025
000283064 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767013510_31205
000283064 3367_ $$033$$2EndNote$$aConference Paper
000283064 3367_ $$2BibTeX$$aINPROCEEDINGS
000283064 3367_ $$2DRIVER$$aconferenceObject
000283064 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283064 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283064 3367_ $$2ORCID$$aOTHER
000283064 520__ $$aWhile knowledge about dementia and its causes is increasing rapidly, healthcare systems remain ill-equipped to detect cognitive decline in the early stages of neurodegenerative diseases such as Alzheimer's disease (AD). However, improving the early identification of AD in the population is a prerequisite for dementia prevention and providing future disease-modifying treatments for individuals most likely to benefit. Subjective cognitive deficits (SCD) and mild cognitive impairment (MCI) may indicate prodromal AD, even in the absence of functional impairment; in conjunction with an AD-typical biomarker profile, the risk of further cognitive decline increases significantly. Offering cognitive and biomarker investigations to individuals with SCD or MCI may therefore open a window of opportunity for early interventions.This project, part of the Davos Alzheimer's Collaborative Healthcare System Preparedness Accurate Diagnosis Project, builds on a network of general practitioners (GPs) and specialists in private practice (neurologists, psychiatrist and geriatricians) in Munich, Germany. We will introduce participating physicians to a proprietary digital cognitive test (developed by Medotrax) and blood-based biomarkers (Roche p-tau217). GP-specialist pairs will be allocated to four groups of centers, with varying access to biomarker tests (Figure 1). The main aim of the study is to assess the percentage of AD diagnoses made with biomarker evidence, with secondary aims including the impact of blood-based and digital investigations on resource utilization and diagnostic workflows.Initial experiences with designing the study protocol, learnings from the recruitment of study sites and insights from study participants will be presented.Currently, there is no system in place for targeted, standardized identification of cases with minimal cognitive decline in Germany or worldwide, hindering efforts to detect neurodegenerative and other causes of cognitive impairment in large segments of the population. The lack of a robust approach for detecting early changes with acceptable accuracy outside of specialist clinics results in disappointingly low diagnostic rates. The COGSCREEN 2 study will help to establish an effective and efficient early diagnosis framework, embedded in a global network of DAC sites.
000283064 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283064 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283064 650_7 $$2NLM Chemicals$$aBiomarkers
000283064 650_7 $$2NLM Chemicals$$atau Proteins
000283064 650_2 $$2MeSH$$aHumans
000283064 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000283064 650_2 $$2MeSH$$aCognitive Dysfunction: blood
000283064 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000283064 650_2 $$2MeSH$$aBiomarkers: blood
000283064 650_2 $$2MeSH$$aNeuropsychological Tests
000283064 650_2 $$2MeSH$$aGermany
000283064 650_2 $$2MeSH$$atau Proteins: blood
000283064 650_2 $$2MeSH$$aEarly Diagnosis
000283064 7001_ $$0P:(DE-2719)9003081$$aHufnagel, Anna$$b1$$udzne
000283064 7001_ $$aKurz, Carolin Isabella$$b2
000283064 7001_ $$aTegethoff, Paulina$$b3
000283064 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70857_099980$$gVol. 21 Suppl 3, no. Suppl 3, p. e099980$$nSuppl 3$$pe099980$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283064 8564_ $$uhttps://pub.dzne.de/record/283064/files/DZNE-2025-1471.pdf$$yOpenAccess
000283064 8564_ $$uhttps://pub.dzne.de/record/283064/files/DZNE-2025-1471.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283064 909CO $$ooai:pub.dzne.de:283064$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000283064 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000283064 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003081$$aExternal Institute$$b1$$kExtern
000283064 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283064 9141_ $$y2025
000283064 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283064 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283064 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000283064 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283064 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283064 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283064 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283064 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283064 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283064 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283064 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283064 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283064 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x0
000283064 980__ $$aabstract
000283064 980__ $$aVDB
000283064 980__ $$aUNRESTRICTED
000283064 980__ $$ajournal
000283064 980__ $$aI:(DE-2719)5000022
000283064 9801_ $$aFullTexts